The Journal of Clinical Psychiatry
May 13, 2026
Andrew van der Vaart, Jeffrey LaPratt, Kimberly Swartz et al.
Objectives: To evaluate the efficacy, safety, and durability of a single 25-mg dose of a proprietary, synthetic formulation of psilocybin with psychological support for reducing chronic suicidal ideation in a treatment-resistant population. Methods: This was an open-label, single-arm study with a 12-week follow-up conducted between March 2022 and May 2025. Twenty adults with chronic suicidal...
Frontiers in Psychiatry
May 13, 2026
Feliciano Yu, Joe Tafur, Francisco Moreno et al.
2 citations
Importance: The Oregon Psilocybin Services (OPS) program is the first statewide, regulated framework for legal psilocybin in the U.S. Analyzing inaugural-year utilization and safety is essential for informing policy and equity monitoring. Methods: We conducted a descriptive analysis of statewide aggregate data from the OPS Public Dashboard (January 1-December 31, 2025). Outcomes included...
Journal of Pre-Clinical and Clinical Research
May 12, 2026
Bartłomiej Kosiarski, A. Skrzypek, Patrycja Markowicz et al.
Rapid-acting interventions in treatment-resistant depression – a comparative review of
Research Square
May 11, 2026
Chloë K Walters, Sarentha Chetty, Thankhoe A Rants’o et al.
preprint
Abstract Background: Conventional pharmacotherapy for treatment-resistant depression (TRD) has been found to provide limited benefit in a subset of patients. Psilocybin‑assisted therapy has emerged as a promising modality due to its rapid‑acting antidepressant effects and favourable tolerability profile shown in early trials. Despite growing research interest in psilocybin‑assisted therapy the...
International Journal of Molecular Sciences
May 9, 2026
Marta Jóźwiak-Bębenista, Anna Stasiak, Monika Sienkiewicz et al.
Aging is associated with chronic, low-grade inflammation ("inflammaging"), which contributes to neuropsychiatric and neurodegenerative disorders such as depression, Alzheimer's disease, and Parkinson's disease. Conventional pharmacotherapies often provide limited benefit in older adults and are further complicated by polypharmacy and drug-drug interactions. Psilocybin, a serotonergic...
Journal of Education, Health and Sport
May 7, 2026
Kinga Zachar, M. Sito, Filip Jurkowski et al.
Introduction and purpose: Depressive disorders, particularly major depressive disorder (MDD) and treatment-resistant depression (TRD), remain major causes of disability worldwide. Conventional treatments are limited by delayed onset, incomplete response, relapse, and adverse effects. This review summarizes current evidence on the efficacy, safety, and durability of psilocybin-assisted therapy...
JAMA Network Open
May 7, 2026
Peter S. Hendricks, Sara N Lappan, Richard C. Shelton et al.
4 citations
Importance: Cocaine use disorder is a serious public health problem and no medications have been proven effective for its treatment. Objective: To evaluate psilocybin in the treatment of cocaine use disorder. It was hypothesized that psilocybin, compared with placebo, would yield a higher percentage of cocaine abstinent days, a greater likelihood of complete abstinence from cocaine, and a...
bioRxiv Preprint Server
May 5, 2026
Povilas Tarailis, Inga Griškova-bulanova
preprint
Electroencephalographic (EEG) microstates provide a compact framework for characterizing the temporal organization of large-scale brain activity, yet their sensitivity to altered brain states remains insufficiently explored. In this study, we applied broadband and frequency-resolved EEG microstate analysis to resting-state EEG data from two publicly available datasets acquired under markedly...
Nature Communications
May 5, 2026
T Lyons, M Spriggs, L Kerkelä et al.
19 citations
Psychedelics have robust effects on acute brain function and long-term behavior but whether they also cause enduring functional and anatomical brain changes is largely unknown. In an exploratory, placebo-controlled, within-subjects, electroencephalography (EEG), and magnetic resonance imaging (MRI) study in 28 healthy, entirely psychedelic-naive participants, anatomical and functional brain...
American Journal of Preventive Medicine
May 4, 2026
Kevin H. Yang, Nora Satybaldiyeva, Wayne Kepner et al.
1 citation
IntroductionMicrodosing involves consuming low doses of psychoactive substances, typically between 1/5th and 1/20th of a recreational dose. Despite increasing public attention to cannabis and psychedelics amid evolving drug policies, epidemiologic data on microdosing remain limited.MethodsA cross-sectional, web-based survey (Characterizing the Epidemiology of Cannabidiol Use Survey) of 1,523...